Business
Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting
Two oral presentations highlighting updated results of PV patients on rusfertide achieving hematocrit control while essentially eliminating phlebotomy
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"Two oral presentations highlighting updated results of PV patients on rusfertide achieving hematocrit control while essentially eliminating phlebotomy\n Additional abstracts to be presented at ASH, providing further clinical and pre-clinical rusfertide data in PV as well as new pharmacology data for rusfertide in HH\n\n\nNEWARK, Calif., Nov. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) (\"Protagonist\" or \"the Company\") today announced that two abstracts highlighting updated data from its Phase 2 study of rusfertide in polycythemia vera (PV) have been selected for oral presentations at the American Society of Hematology (ASH) 2021 Annual Meeting taking place December 11-14, 2021. An additional three abstracts on rusfertide in PV and hereditary hemochromatosis (HH) have been accepted as poster presentations at ASH.\n\"We are delighted to have the opportunity to present further evidence of rusfertide's potential to improve outcomes in polycythemia vera and other diseases related to iron dysregulation,\" said Dinesh V. Patel, PhD, President and Chief Executive Officer of Protagonist. \"Data included in these oral presentations will provide important new information about how rusfertide may reduce the need for phlebotomy and control hematocrit levels and symptoms for patients suffering from PV. The data we share at ASH this year will serve as a valuable springboard for further advancement of our rusfertide clinical programs, including the initiation of a Phase 3 clinical trial of rusfertide in PV in the first quarter of 2022.\"\nDetails for ASH 2021 oral presentations are as follows:\nTitle: \"Rusfertide (PTG-300) Controls Hematocrit Levels and Essentially Eliminates Phlebotomy Requirement in Polycythemia Vera Patients\"Session Title: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for MyelofibrosisPresentation Type: OralPresentation Date and Time: Sunday, December 12, 2021/Session Time: 9:30 AM - 11:00 AM/Presentation Time: 10:15 AMAuthors: Ronald Hoffman, MD, Marina Kremyanskaya, MD, PhD, Yelena Ginzburg, MD, Andrew Kuykendall, MD, Naveen Pemmaraju, MD, Abdulraheem Yacoub, MD, Jay Yang, MD, Suneel Gupta, PhD, Frank Valone, MD, Sarita Khanna, PhD and Srdan Verstovsek, MD, PhD\nTitle: \"Rusfertide (PTG-300) Induction Therapy Rapidly Achieves Hema...